semaglutide nash phase 3 A Placebo-Controlled Trial of Subcutaneous in Nonalcoholic Steatohepatitis Exciting Phase 3 Data from

Semaglutide is a GLP-1 receptor agonist that regulates blood glucose, slows gastric emptying, and reduces appetite

Tirzepatide is FDA-approved for the treatment of: Weight management Type 2 diabetes Obstructive sleep apnea The brand names for tirzepatide are: Mounjaro Zepbound In a clinical study, tirzepatide demonstrated a weight loss advantage of 2.4% after three months compared to the semaglutide group (27)

It also decreases the amount of glucose produced by the liver and slows down the rate at which the stomach empties

Bear in mind though that these drinks contain sugars, calories and electrolytes, which are all helpful in moderation, but can lead to an excessive intake of these components if consumed in large amounts